Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J A Zujewski

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
British Journal of Cancer|July 1, 1996
Deficient DNA repair capacity, a predisposing factor in breast cancerR Parshad, F M Price, V A Bohr, et al.
Journal of Cancer Policy|July 29, 2020
Promoting evidence-based practices for breast cancer care through web-based collaborative learningM K Cira, R Tesfay, J A Zujewski, et al.
The Pharmacogenomics Journal|August 9, 2017
Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanesC F Spraggs, L R Parham, L P Briley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 1999
Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patientsK H Cowan, J A Moscow, H Huang, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
British Journal of Cancer|July 1, 1996
Deficient DNA repair capacity, a predisposing factor in breast cancerR Parshad, F M Price, V A Bohr, et al.
Journal of Cancer Policy|July 29, 2020
Promoting evidence-based practices for breast cancer care through web-based collaborative learningM K Cira, R Tesfay, J A Zujewski, et al.
The Pharmacogenomics Journal|August 9, 2017
Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanesC F Spraggs, L R Parham, L P Briley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 1999
Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patientsK H Cowan, J A Moscow, H Huang, et al.
Pageof 1